Monday Headlines:
Deep Dive: They started out treating type 2 diabetes. Now hundreds of thousands of Australians are taking them, many for a completely different reason.
GLP-1s. You probably know them as Ozempic, Wegovy and Mounjaro.
And the more people sign up, the longer the fine print gets. There are side effects GPs are still learning about, prices many can’t afford, and growing concern about online clinics posting pens to people they’ve never met.
So, years after they went from diabetes medication to weight-loss wonder drug... what do we actually know about them?
In this episode of The Briefing, Chris Spyrou is joined by Dr Michael Wright, President of the Royal Australian College of GPs, to unpack what we’ve learnt about these drugs, who should be taking them, and who definitely shouldn’t.
Follow The Briefing:
TikTok: @thebriefingpod
Instagram: @thebriefingpodcast
YouTube: @TheBriefingPodcast
See omnystudio.com/listener for privacy information.